406 related articles for article (PubMed ID: 18986296)
1. Clinical trial design and consequences for drug development for community-acquired pneumonia: an industry perspective.
Tillotson GS; Echols RM
Clin Infect Dis; 2008 Dec; 47 Suppl 3():S237-40. PubMed ID: 18986296
[TBL] [Abstract][Full Text] [Related]
2. Clinical trial design for mild-to-moderate community-acquired pneumonia--an industry perspective.
Echols RM; Tillotson GS; Song JX; Tosiello RL
Clin Infect Dis; 2008 Dec; 47 Suppl 3():S166-75. PubMed ID: 18986284
[TBL] [Abstract][Full Text] [Related]
3. Scenario 1: a patient with mild community-acquired pneumonia--introduction to clinical trial design issues.
Gilbert DN
Clin Infect Dis; 2008 Dec; 47 Suppl 3():S121-2. PubMed ID: 18986276
[TBL] [Abstract][Full Text] [Related]
4. Overview of recent studies of community-acquired pneumonia.
Higgins K; Singer M; Valappil T; Nambiar S; Lin D; Cox E
Clin Infect Dis; 2008 Dec; 47 Suppl 3():S150-6. PubMed ID: 18986282
[TBL] [Abstract][Full Text] [Related]
5. Clinical and microbiological end points in the treatment of pneumonia.
Musher DM
Clin Infect Dis; 2008 Dec; 47 Suppl 3():S207-9. PubMed ID: 18986291
[TBL] [Abstract][Full Text] [Related]
6. Is activity against "atypical" pathogens necessary in the treatment protocols for community-acquired pneumonia? Issues with combination therapy.
Bartlett JG
Clin Infect Dis; 2008 Dec; 47 Suppl 3():S232-6. PubMed ID: 18986295
[TBL] [Abstract][Full Text] [Related]
7. Is it possible to blind a trial for community-acquired pneumonia?
Boucher HW
Clin Infect Dis; 2008 Dec; 47 Suppl 3():S210-5. PubMed ID: 18986292
[TBL] [Abstract][Full Text] [Related]
8. Use of pharmacokinetics and pharmacodynamics in a failure analysis of community-acquired pneumonia: implications for future clinical trial study design.
Ambrose PG
Clin Infect Dis; 2008 Dec; 47 Suppl 3():S225-31. PubMed ID: 18986294
[TBL] [Abstract][Full Text] [Related]
9. Historical and regulatory perspectives on the treatment effect of antibacterial drugs for community-acquired pneumonia.
Singer M; Nambiar S; Valappil T; Higgins K; Gitterman S
Clin Infect Dis; 2008 Dec; 47 Suppl 3():S216-24. PubMed ID: 18986293
[TBL] [Abstract][Full Text] [Related]
10. Challenges in the design and conduct of clinical trials for hospital-acquired pneumonia and ventilator-associated pneumonia: an industry perspective.
Barriere SL
Clin Infect Dis; 2010 Aug; 51 Suppl 1():S4-9. PubMed ID: 20597670
[TBL] [Abstract][Full Text] [Related]
11. Efficacy as an important facet of "safety" in clinical trials: how can we do our best for our patients?
Talbot GH
Clin Infect Dis; 2008 Dec; 47 Suppl 3():S180-5. PubMed ID: 18986286
[TBL] [Abstract][Full Text] [Related]
12. Clinical end points of therapy for patients with mild community-acquired pneumonia.
Gilbert DN
Clin Infect Dis; 2008 Dec; 47 Suppl 3():S140-4. PubMed ID: 18986280
[TBL] [Abstract][Full Text] [Related]
13. Unique considerations in the evaluation of antibacterials in clinical trials for pediatric community-acquired pneumonia.
Bradley JS; McCracken GH
Clin Infect Dis; 2008 Dec; 47 Suppl 3():S241-8. PubMed ID: 18986297
[TBL] [Abstract][Full Text] [Related]
14. Treatment costs associated with community-acquired pneumonia by community level of antimicrobial resistance.
Asche C; McAdam-Marx C; Seal B; Crookston B; Mullins CD
J Antimicrob Chemother; 2008 May; 61(5):1162-8. PubMed ID: 18310136
[TBL] [Abstract][Full Text] [Related]
15. Role of gemifloxacin in community-acquired pneumonia.
Tillotson GS
Expert Rev Anti Infect Ther; 2008 Aug; 6(4):405-18. PubMed ID: 18662107
[TBL] [Abstract][Full Text] [Related]
16. Antibacterial drug resistance: implications for the treatment of patients with community-acquired pneumonia.
Metlay JP
Infect Dis Clin North Am; 2004 Dec; 18(4):777-90. PubMed ID: 15555824
[TBL] [Abstract][Full Text] [Related]
17. How long should we treat community-acquired pneumonia?
Scalera NM; File TM
Curr Opin Infect Dis; 2007 Apr; 20(2):177-81. PubMed ID: 17496577
[TBL] [Abstract][Full Text] [Related]
18. End points in hospital-acquired pneumonia and/or ventilator-associated pneumonia clinical trials: food and drug administration perspective.
Laessig KA
Clin Infect Dis; 2010 Aug; 51 Suppl 1():S117-9. PubMed ID: 20597659
[TBL] [Abstract][Full Text] [Related]
19. Guidelines for treatment of community-acquired pneumonia.
Kim MK; Nightingale C; Quintiliani R
Conn Med; 2001 Aug; 65(8):473-5. PubMed ID: 11550446
[No Abstract] [Full Text] [Related]
20. Community acquired pneumonia.
Loeb M
Clin Evid; 2002 Jun; (7):1358-68. PubMed ID: 12230751
[No Abstract] [Full Text] [Related]
[Next] [New Search]
